EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallbericht

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile

Hélène Marchandin iD, Cyril Anjou iD, Gaëtan Poulen, Jane Freeman, Mark Wilcox iD, Hélène Jean-Pierre, Frédéric Barbut

Journal of Antimicrobial Chemotherapy · 2023

DOI: 10.1093/jac/dkad194 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Hélène Marchandin und 6 weiteren Autor:innen. Beteiligte Einrichtung: HydroSciences Montpellier, University of Montpellier, CNRS, IRD, Microbiology and Infection Control Laboratory, Nîmes University Hospital, Montpellie…. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fidaxomicin is a first-line treatment for Clostridioides difficile infections (CDIs). Fidaxomicin resistance has rarely been reported in this urgent antimicrobial resistance threat as defined by the CDC.

Objectives

To report a case of fidaxomicin-resistant C. difficile isolation in a patient treated by fidaxomicin, characterize the genetic determinant for resistance and the consequences on pathophysiological traits, and review the literature. Patient and methods A 38-year-old male patient with several risk factors for CDI experienced three episodes of hospital-acquired CDI and received fidaxomicin for the first episode. The successive isolates were subjected to phenotypic characterization (antimicrobial susceptibility, growth, sporulation ability and toxin production) and WGS analysis to evaluate clonality and modifications associated with resistance.

Results

Resistance to fidaxomicin arose in isolates from the recurrences of CDI (MIC: 16 mg/L). WGS analysis showed a close genetic link between strains suggestive of relapses in this patient. A T3428G mutation in the rpoB gene might be associated with fidaxomicin resistance. The resistance was associated with defects in growth, sporulation and production of toxins. A review of the literature found only three previous fidaxomicin-resistant C. difficile clinical strains.

Conclusions

Although rarely reported, resistance to fidaxomicin may quickly emerge in vivo after a single course of treatment. This observation supports the need for prospective surveillance of the susceptibility of C. difficile to treatment antibiotics. However, the clinical relevance of fidaxomicin resistance still needs to be elucidated, particularly due to its apparent rareness and associated fitness cost.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsHumansAdultFidaxomicinAnti-Bacterial AgentsClostridioidesProspective StudiesDrug Resistance, Bacterial

Substanzen

FidaxomicinAnti-Bacterial Agents

Autor:innen und Institutionen

  • HydroSciences Montpellier, University of Montpellier, CNRS, IRD, Microbiology and Infection Control Laboratory, Nîmes University Hospital, Montpellier 34093, France.
  • Institut Pasteur Laboratory Pathogenesis of Bacterial Anaerobes, Université Paris Cité, Paris 75015, France.
  • Neurosurgery Department, Montpellier University Hospital, Montpellier 34295, France.
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Clostridioides difficile (ESGCD), Basel, Switzerland.
  • Healthcare Associated Infection Research Group, Leeds Teaching Hospitals National Health Service (NHS) Trust & University of Leeds, Leeds LS1 3EX, UK.
  • Maladies Infectieuses et Vecteurs-Écologie, Génétique, Évolution et Contrôle, University of Montpellier, CNRS, IRD, Bacteriology Laboratory, Montpellier University Hospital, Montpellier 34295, France.

ORCID-Profile: Hélène Marchandin, Cyril Anjou, Mark Wilcox

Zitieren

APA

Marchandin, H., Anjou, C., Poulen, G., Freeman, J., Wilcox, M., Jean-Pierre, H., & Barbut, F. (2023). In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad194

Vancouver

Marchandin H, Anjou C, Poulen G, Freeman J, Wilcox M, Jean-Pierre H, et al. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad194

BibTeX
@article{Marchandin2023,
  author = {Marchandin, Hélène and Anjou, Cyril and Poulen, Gaëtan and Freeman, Jane and Wilcox, Mark and Jean-Pierre, Hélène and Barbut, Frédéric},
  title = {In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  doi = {10.1093/jac/dkad194}
}
Kostenlos starten →